Leadership & Pay ·
Effective July 20, 2026, Phio Pharmaceuticals Corp. increased its Board of Directors to six members and appointed R.…
PHIOPhio Pharmaceuticals Corp.
Effective July 20, 2026, Phio Pharmaceuticals Corp. increased its Board of Directors to six members and appointed R. Todd Plott, M.D. to the Board and the Governance Committee. Dr. Plott is a board-certified dermatologist and former FDA advisory committee member with over 30 years of experience, intended to support the advancement of PH-762 for squamous cell carcinoma. He will receive standard non-employee director compensation and equity awards. The company is a clinical-stage biopharmaceutical company developing siRNA therapeutics using INTASYL technology to treat cancer.